AstraZeneca (LON:AZN) had its price objective lifted by Barclays from GBX 7,000 ($91.47) to GBX 7,200 ($94.08) in a report issued on Friday, Borsen Zeitung reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective suggests a potential upside of 19.74% from the company’s current price.
Several other research analysts have also weighed in on AZN. JPMorgan Chase & Co. set a GBX 7,100 ($92.77) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Tuesday, January 29th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Tuesday, February 5th. Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a research note on Thursday, February 14th. Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the stock a “sell” rating in a research note on Thursday, February 14th. Finally, Jefferies Financial Group set a GBX 6,100 ($79.71) price target on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Thursday, February 14th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and a consensus price target of GBX 6,425.16 ($83.96).
AstraZeneca stock opened at GBX 6,013 ($78.57) on Friday. AstraZeneca has a fifty-two week low of GBX 5,110 ($66.77) and a fifty-two week high of GBX 6,540 ($85.46). The company has a market cap of $78.88 billion and a P/E ratio of 31.65. The company has a debt-to-equity ratio of 179.66, a quick ratio of 0.57 and a current ratio of 0.75.
In other AstraZeneca news, insider Philip A. J. Broadley acquired 520 shares of the stock in a transaction dated Tuesday, April 30th. The shares were bought at an average cost of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer acquired 8,500 shares of the stock in a transaction dated Tuesday, May 7th. The stock was acquired at an average price of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Roth IRA
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.